Scalper1 News
The FDA said Thursday that it’s requiring that a warning of liver damage be put on the labels of AbbVie’s (ABBV) hepatitis C treatments Viekira Pak and Technivie, sending AbbVie shares plunging to an 18-month low and those of Gilead Sciences (GILD) up sharply. “Our review of adverse events reported to the FDA Adverse Event Reporting System (FAERS) database and to the manufacturer of these medicines, AbbVie, identified cases of hepatic Scalper1 News
Scalper1 News